MANKIND PHARMA LTD Q3 RESULTS
RVNL among India Inc's unlucky 13 with over 25% drop in both sales, profit in Q1
To maintain a premium valuation, a stock must demonstrate strong earnings growth and a positive future outlook. However, the June quarter results revealed that several prominent companies, including popular retail multibaggers, fell short in terms of earnings. ETMarkets reviewed companies with an m-cap of at least Rs 5,000 crore and identified 13 entities that reported at least a 25% YoY decline in sales and profit.
Bino Pathiparampil expects positive momentum in pharma sector; has 3 top picks
Bino Pathiparampil of Elara Capital discussed the strong Q1 FY25 performance in the pharma sector. Companies like Lupin and Dr Reddy's received upgrades, largely due to their success in the US market. Despite high valuations, the sector's positive momentum is likely to persist, with Zydus Lifesciences noted for future product launches.
Glenmark Q1 Results: Net profit doubles to Rs 340 crore
Glenmark Pharma net profit doubled to Rs 340 crore crore in Q1FY25 led by robust sales growth in India and Europe and reduction in finance, depreciation and ammortisation costs.
Alembic Pharma Q1 Results: Net profit rises 12% YoY to Rs 135 crore
Earnings before interest, tax, depreciation and amortisation (EBITDA) rose 14% YoY to Rs 239 crore, while the EBITDA margins contracted 540 basis points on y-o-y basis to 15.3%
Lupin shares surge 6%, hit 52-week high post robust Q1 result
Lupin Share Price: Lupin's shares jumped 6% to a 52-week high after the company announced a 77.2% increase in net profit for the June quarter of FY25. The firm's net profit was Rs 801.3 crore, and revenue rose 16.3% to Rs 5,600.3 crore. Nomura maintained a 'Buy' rating, forecasting continued growth.
Q1 results today: Vedanta among 132 companies to announce earnings on Tuesday
During the first quarter earnings season, 132 companies, including PFC and Tata Power, were scheduled to announce their financial results. Vedanta's net profit was expected to range between Rs 2,197-3,060 crore, with revenue estimates between Rs 35,440-38,674 crore for June 2024. Different brokerages provided varying growth predictions.
- Go To Page 1
Sun Pharma Q1 Results: Net profit rises 40% YoY to Rs 2,836 crore, beats estimates
Sun Pharma Q1 Results: Sun Pharma reported a 40% increase in consolidated net profit to Rs 2,836 crore, surpassing estimates of Rs 2,638 crore. Revenue rose 6% YoY to Rs 12,653 crore. EBITDA grew 8% YoY to Rs 3,608 crore with margins at 28.5%. India formulation sales reached Rs 4,144 crore, up 16%, constituting 33.1% of total sales.
Mankind Pharma shares drop 2% despite 10% YoY Q1 PAT growth. Buy, sell, or hold?
Mankind Pharma's shares fell 2% to Rs 1,985.50, despite the company announcing a 10% YoY rise in net profit to Rs 543 crore for the first quarter of FY25. Revenues increased 12% YoY to Rs 2,893 crore. Brokerages had mixed reactions, with Macquarie, Motilal Oswal, and Kotak Equities offering varied recommendations.
Q1 results today: ITC, Tata Motors among 88 companies will announce earnings on Thursday
Earnings season commenced with 88 companies announcing results. Key highlights included ITC, Sun Pharma, Tata Motors, Adani Enterprises, and Zomato reporting. ITC and Dabur anticipated revenue growth from cigarettes, hotels, and FMCG segments. Tata Motors projected strong profit growth. Zomato maintained robust performance from prior quarters, offering promising outlooks.
Be a bit cautious in auto stocks and do not chase the particular rally in Maruti: Dipan Mehta
Dipan Mehta of Elixir Equities discussed the outlook for the auto and cement industries, noting potential slowdowns and increased competition. He commented on recent developments in speculative trading regulations, the pharma sector, and the performance of companies like Zomato, Paytm, and Maruti. Mehta advised caution in the auto sector while expressing optimism about select pharma stocks.
Mankind Pharma Q1 Results: Net profit jumps 10% to Rs 543 crore
The drug maker reported net profit of Rs 494 crore in the corresponding period of previous year.Revenue from operations rose 12.2% YoY to Rs 2,893 crore in Q1FY25. On a quarter-on-quarter (QoQ) basis revenue and net profit increased 18.5% and 14%, respectively.
Mankind Pharma Q1 Results: Profit rises 10% YoY to Rs 543 crore
Mankind Pharma Q1 Results: Revenue from operations for the same period increased by 12% year-on-year (YoY) to Rs 2,893 crore, up from Rs 2,579 crore in the previous year. The company reported an EBITDA of Rs 681 crore, reflecting a 4% YoY increase. However, margins for the quarter declined by 188 basis points to 23.54%.
Q1 results today: Maruti, M&M among 115 companies to announce earnings on Wednesday
Q1 results today: In the first quarter earnings season, 115 companies announced results, including Maruti, M&M, Coal India, Adani Power, Tata Steel, Ambuja, and Bank of Baroda. M&M and Maruti expected mixed revenue and profit changes, while Tata Steel's profit was predicted to rise notably amid a revenue drop. Several others also reported their quarterly performance.
Q1 results today: Tata Consumer, Varun Beverages among 91 companies to announce earnings on Tuesday
Q1 Results Today: As first quarter earnings season progressed, 91 companies, like IOC and Tata Consumer, disclosed results. Tata Consumer is expected to exhibit 13% revenue growth due to strong India foods business. However, profit estimates vary. The company's EBITDA margin for the first quarter is projected to rise to 15.3% due to better gross margins.
Q1 results this week: ITC, SBI, TaMo, Zomato among 130 firms to announce earnings
This week, several prominent companies released their June quarter financial results. Firms like ITC, SBI, Adani Ports, Tata Motors, and M&M showcased their reports between July 29th and August 3rd. The updates offered a glimpse into their quarterly performance, engaging the attention of investors and stakeholders.
Q1 results today: IndiGo, IndusInd among 69 companies to announce earnings on Friday
Companies like Aarti Drugs, Amber Enterprises, Bandhan Bank, Cholamandalam Investment, City Union Bank, ESAF SFB, Equitas SFB, Mangalam Organics, Piramal Pharma, TTK Prestige among others will also declare their results.
Mankind trumps EQT-ADIA to buy BSV for $1.67 bn
This is the largest acquisition by Mankind Pharma, India’s 4th largest pharma company by market share. A formal announcement regarding the deal is likely by this week.
Mankind Pharma competes with EQT-ADIA combo for Rs 14,000 cr buyout of BSV Group from Advent
The buyout of BSV Group (formerly Bharat Serum & Vaccines Ltd) is contested by Mankind Pharma and EQT with ADIA, each offering around Rs 14,000 crore ($1.6 billion). This acquisition, one of India's largest pharma buyouts, will significantly impact the domestic market and mark a successful exit for Advent International.
TCS, Infy power D-Street to fresh record highs! Sensex soars 900 points, Nifty tops 24,500 for the first time
Indian markets rose Friday, led by TCS's strong June quarter. Sensex climbed 281 points, Nifty50 up 93 points. Stocks like TCS, Infosys, and Adani Ports surged. Maruti fell. US inflation data raised September Fed rate cut chances, noted by CME FedWatch. RBI's Das predicted 5% retail inflation. Powell's testimony hinted at possible rate cuts.
Stocks in news: Delta Corp, Paytm, Delhivery, Mankind Pharma, JSW Steel
Sensex and Nifty hit records. Delta Corp's Q1 profit dips 34% to Rs 40.48 crore from Rs 61.43 crore last year. Paytm's One97 Communications faces labor notice. Bandhan Bank staff seek legal aid. JSW Steel updates production. Delhivery's equity sold by pension board. Hema CIPEF to sell Mankind Pharma stake. RVNL wins Nagpur Metro project. Mahindra cuts XUV700 price.
Q1 Earnings Preview: Flat to 4% growth in net profit expected from Nifty pack; auto, financials, health to outperform
Motilal Oswal and Kotak Mahindra differ in their Q2 earnings projections for the Nifty universe. While Kotak forecasts a nearly flat growth of 0.6%, Motilal Oswal projects a 4% increase in net profits. Both firms predict stronger growth when excluding global commodities. Motilal Oswal anticipates a 10% YoY increase for the Nifty excluding oil & gas and metals, while Kotak forecasts a 9.3% rise excluding oil marketing companies.
Torrent Pharma, Glenmark Pharma shares jump up to 9% after Q4 results
Shares of Torrent Pharma and Glenmark Pharma surged post Q4 results. Torrent Pharma's net profit jumped 56% YoY while Glenmark Pharma reported increased losses. Motilal Oswal provides target prices for both companies.
Stocks with tailwinds called advantage India: 5 largecap stocks from 3 different sectors with an upside potential of upto 36 %
In terms of valuations and sentiment we are not far from the place where we were in the last quarter of 2023 or early part of this year. When it was not possible to find stocks which can be called as “fairly valued” forget “undervalued”, and the sentiment was very bullish. The only difference between then and now is that we have election results which are coming up. Surely a confirmation on 4th June that continuity in the policy making is a big factor. But there is another thing which long term investors need to look at before investing. Whether the company or the sector has an advantage due to India as a country. A well known example, which has been present for decades is that of the IT industry. India as a country is a factory of software engineers, and that is our strength. So when investing for the long term, look at sectors where we have some strong tailwinds due to our human capital.
Q4 results today: LIC, NMDC among 236 companies to announce earnings on Monday
236 companies, including LIC and NMDC, to announce Q4 results. LIC reported a 49% rise in Q3 earnings, while NMDC saw a 62% increase in consolidated net profit.
Glenmark Pharma Q4 Results: Net loss widens to Rs 121 crore YoY
Glenmark Pharma Q4 Results: The rise in loss was on account of declining sales in the US and exceptional items. It had reported a net loss of Rs 34.5 crore in the corresponding quarter of the previous year. In FY24, Glenmark's consolidated revenue reached Rs. 11,813 crore, a 2% increase year-over-year. The company's EBITDA margin for the fiscal year was 10.1%, primarily due to a one-time impact on sales in the India business during the third quarter.
Sun Pharma Q4 Results: Profit jumps 34% YoY to Rs 2,654 crore, meets Street estimates
Sun Pharma Q4 Results: The company's revenue rose 10% year-on-year to Rs 11,983 crore in the reporting quarter. It was Rs 10,931 crore a year ago. Its board has approved a final dividend of Rs 5 per share, which will be paid within the prescribed timeline. India formulations sales were Rs 3,707 crore for the fourth quarter, showing growth of 10% over Q4 last year and accounted for 31.4% of total consolidated sales for the quarter.
Mankind Pharma Q4 Results: Net profit jumps 62% YoY to Rs 477 crore
Mankind Pharma on Wednesday reported 62% year-on-year (YoY) jump in net profit to Rs 477 crore in Q4FY24 led by strong domestic formulation sales and one-off US export opportunities.
Mankind Pharma Q4 Results: PAT zooms 62% YoY to Rs 477 crore, revenue jumps 19%
Mankind Pharma Q4 Results: The revenue from operations stood at Rs 2,441 crore versus Rs 2,053 crore reported in the year-ago period. Its board approved the raising of funds worth Rs 7,500 crore via the issuance of equity shares. For the full financial year, the consolidated PAT stood at Rs 1,942 crore as against Rs 1,310 crore reported in FY23.
Mankind Pharma Q3 Results: Net profit jumps 56% YoY to Rs 460 crore
Mankind Pharma on Wednesday reported a 56% year-on-year (YoY) jump in net profit to Rs 460 crore in Q3FY24 led by strong domestic formulation sales and one-off US export opportunities.
Load More
